Page 5 - சமீப வணிக சிறப்பம்சங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சமீப வணிக சிறப்பம்சங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சமீப வணிக சிறப்பம்சங்கள் Today - Breaking & Trending Today

Aehr Test Systems Reports Second Quarter Fiscal 2021 Financial Results

Aehr Test Systems Reports Second Quarter Fiscal 2021 Financial Results
Aehr Test Systems Reports Second Quarter Fiscal 2021 Financial Results
FREMONT, Calif., Jan. 07, 2021 Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced financial results for its second quarter of fiscal 2021 ended November 30, 2020.
Fiscal Second Quarter Financial Results:
Net sales were $1.7 million, compared to $6.9 million in the second quarter of fiscal 2020.
GAAP net loss was $2.0 million, or $0.08 per diluted share, compared to GAAP net income of $251,000, or $0.01 per diluted share, in the second quarter of fiscal 2020.
Non-GAAP net loss was $1.7 million, or $0.07 per diluted share, which excludes the impact of stock-based compensation, compared to non-GAAP net income of $456,000, or $0.02 per diluted share, in the second quarter of fiscal 2020. ....

United States , Gayn Erickson , Exchange Commission , Securities Exchange , Aehr Test Systems , Second Quarter Financial Results , First Six Months Financial Results , Business Impacts , Revenue Negatively Impacted , Customer Evaluations , Orders Experienced Delays , While Aehr , Cost Reductions Implemented , Expected Orders , Second Quarter , Recent Business Highlights , Diepak Carriers , Conference Call , Webcast Aehr Test Systems , Investor Relations , Aehr Test Systems Headquartered , Aehr Test , Pak Contactor , Diepak Carrier , Harbor Statement This , Securities Act ,

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
KVD900 Phase 2 Clinical Trial Patient Treatment Completed; Data Expected Q1 2021 -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2020.
We have completed the patient treatment phase of our KVD900 Phase 2 trial and are in the process of wrapping up that study. Data from this trial evaluating KVD900 as an oral on-demand treatment for hereditary angioedema is expected in the first quarter of 2021, said Andrew Crockett, Chief Executive Officer of KalVista. The formulation data recently shared for KVD824, our oral prophylactic treatment candidate for HAE, showed concentrations that we believe can lead to efficacy levels compe ....

Leah Monteiro , Andrew Crockett , Exchange Commission , Kalvista Pharmaceuticals Inc , European Medicines Agency , Drug Administration , Corporate Communications Investor Relations , Trial Patient Treatment Completed , Vista Pharmaceuticals , Chief Executive Officer , Investigational New Drug Application , Fiscal Quarter , Recent Business Highlights , Pediatric Investigational Plan , Fiscal Quarter Financial Results , Merck Option Agreement , Kalvista Pharmaceuticals , Securities Litigation Reform Act , Consolidated Statement , Consolidated Statements , லியா மான்டீரோ , ஆண்ட்ரூ குரோக்கெட் , பரிமாற்றம் தரகு , பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , சோதனை நோயாளி சிகிச்சை நிறைவு , விஸ்டா மருந்துகள் ,